English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  To explore the inhibitory effect of bevacizumab, a vascular endothelial growth factor antibody, on angiogenesis in human osteosarcoma of nude mice.    Methods  Twenty‐one nude mice were inoculated with red fluorescent protein ( RFP )‐labeled human osteosarcoma cell line 143 B‐RFP, that is,  clones that expressed  RFP  in the cytoplasm, and randomly assigned to one of three groups:  G1  ( C ontrol group, injected with saline solution);  G 2 (intraperitoneal bevacizumab 2 mg/kg twice per week) and  G 3 (intraperitoneal bevacizumab 5 mg/kg, twice per week). The tumor‐bearing mice were examined in a fluorescence light box that was illuminated periodically. The primary tumors were measured by fluorescence imaging weekly and their volumes calculated.    Results  The mean tumor volumes were significantly smaller in the  G 3 (186.4 ± 100.8 mm 3 ) than the control group (587.0 ± 406.8 mm 3 ) ( P  < 0.05) on Day 31, and again significantly smaller in the  G 3 (677.3 ± 461.9 mm 3 ) than the control group (3162.6 ± 1529.2 mm 3 ) on Day 38 ( P  < 0.01). The average tumor volume in the  G 2 group was 493.5 ± 425.4 mm 3  on Day 31 and 1870.1 ± 1524.8 mm 3  on Day 38. The effect on tumor volume was greater in the  G 3 than the  G 2 group. Three mice in the  G 2 group, four in the  G 3 group and four in the control group developed lung metastases that were confirmed by pathological examination; these differences were not statistically significant ( P  < 0.05).    Conclusions  Bevacizumab exhibits strong antiangiogenesis activity in experimental osteosarcoma in a nude mouse model but does not influence the incidence of lung metastasis. Our findings may have considerable potential for the treatment of osteosarcoma.

Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab